Ferring Pharmaceuticals today announced that Michel Pettigrew, President of the Executive Board and Chief Operating Officer, will retire from his operational activities effective December 31, 2018. Per Falk, Chief Science Officer, will assume additional responsibility as President of the Executive Committee, effective January 1, 2019. “I would like to express my sincere appreciation for Michel’s commitment to Ferring, his considerable achievements and his passion for supporting patients and helping people live better lives”
